H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen.

On April 29, 2026, H.C. Wainwright hiked Relay Therapeutics, Inc. (NASDAQ:RLAY)’ price target from $19 to $25. It also maintained a Buy rating on the stock. The firm noted Phase 1 zovegalisib triplet results that “derisk” the anticipated Phase 3 study.

On May 5, 2026, Relay Therapeutics, Inc. (NASDAQ:RLAY) announced that the FDA had granted Breakthrough Therapy designation to zovegalisib paired with fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer, which the Phase 1/2 ReDiscover study findings supported. At ESMO TAT, the company reported 400mg BID doublet results. It showed 11.1 months of median progression-free survival in severely pre-treated patients, with essentially equal efficacy across kinase and non-kinase variants.

For frontline breast cancer, Relay Therapeutics, Inc. (NASDAQ:RLAY) chose zovegalisib plus atirmociclib as the next triplet, with a 44% objective response rate in median third-line patients at unoptimized dosages. A Phase 3 trial aimed at endocrine sensitive patients is planned to begin in early 2027, with Pfizer providing atirmociclib.

Relay Therapeutics, Inc. (NASDAQ:RLAY) ended the first quarter with $642.1 million in cash from $554.5 million at the end of the previous year. It also stated that existing finances would sustain operations through 2029.

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a firm that works to transform the drug discovery process. It focuses on advancing small-molecule therapeutic discovery in targeted oncology.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.